148 related articles for article (PubMed ID: 22285964)
1. Phase II studies in soft tissue sarcoma: time for reappraisal.
Sleijfer S
Oncologist; 2012; 17(2):154-6. PubMed ID: 22285964
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Ray-Coquard I; Italiano A; Bompas E; Le Cesne A; Robin YM; Chevreau C; Bay JO; Bousquet G; Piperno-Neumann S; Isambert N; Lemaitre L; Fournier C; Gauthier E; Collard O; Cupissol D; Clisant S; Blay JY; Penel N;
Oncologist; 2012; 17(2):260-6. PubMed ID: 22285963
[TBL] [Abstract][Full Text] [Related]
3. Objective response to sorafenib in advanced clear-cell sarcoma.
Mir O; Boudou-Rouquette P; Larousserie F; Babinet A; Dumaine V; Anract P; Goldwasser F
Ann Oncol; 2012 Mar; 23(3):807-809. PubMed ID: 22274882
[No Abstract] [Full Text] [Related]
4. Sorafenib is active on lung metastases from synovial sarcoma.
Basso U; Brunello A; Bertuzzi A; Santoro A
Ann Oncol; 2009 Feb; 20(2):386-7. PubMed ID: 19211500
[No Abstract] [Full Text] [Related]
5. About sorafenib in castration-resistant prostate cancer.
Colloca G; Checcaglini F; Venturino A
Ann Oncol; 2008 Oct; 19(10):1812-3; author reply 1813-1814. PubMed ID: 18689865
[No Abstract] [Full Text] [Related]
6. Sorafenib and sunitinib.
Kim A; Balis FM; Widemann BC
Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
[No Abstract] [Full Text] [Related]
7. Sorafenib for HCC: a pragmatic perspective.
Razumilava N; Gores GJ
Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
[No Abstract] [Full Text] [Related]
8. Targeting ELF in therapy of liver cancer.
Cancer Biol Ther; 2007 Jul; 6(7):997. PubMed ID: 19358343
[No Abstract] [Full Text] [Related]
9. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
10. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Zhu AX
Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
[No Abstract] [Full Text] [Related]
11. Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Di Maio M; Daniele B; Perrone F
Nat Rev Clin Oncol; 2009 Sep; 6(9):505-6. PubMed ID: 19707242
[No Abstract] [Full Text] [Related]
12. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
13. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
14. Health-related quality of life and sorafenib.
Spinzi G; Terreni N
Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
[No Abstract] [Full Text] [Related]
15. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Burak KW
Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
[No Abstract] [Full Text] [Related]
16. Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Kim DY; Han KH
J Gastroenterol Hepatol; 2011 Nov; 26(11):1585-6. PubMed ID: 22011294
[No Abstract] [Full Text] [Related]
17. Antiangiogenic therapy: not just for cancer anymore?
Shah VH; Bruix J
Hepatology; 2009 Apr; 49(4):1066-8. PubMed ID: 19330868
[No Abstract] [Full Text] [Related]
18. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
19. Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series.
Roubaud G; Kind M; Coindre JM; Maki RG; Bui B; Italiano A
Ann Oncol; 2012 Mar; 23(3):804-805. PubMed ID: 22294526
[No Abstract] [Full Text] [Related]
20. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Vitale A; Lombardi G; Ramirez Morales R; Cillo U
Dig Liver Dis; 2012 May; 44(5):361-2. PubMed ID: 22424640
[No Abstract] [Full Text] [Related]
[Next] [New Search]